DEC TIMOTHY C 4

What Happened Timothy C. Dec, Senior Vice President and Chief Financial Officer of Supernus Pharmaceuticals (SUPN), was credited with two award entries of 3,000 derivative shares each on February 28, 2026 — a total of 6,000 performance-based share units (PSUs). Each grant shows an acquisition price of $0, indicating these are compensation awards (derivative/award transactions), not open-market purchases or sales. The Form 4 covering these transactions was filed on March 3, 2026.

Key Details

• Transaction date: 2026-02-28; Form 4 filed: 2026-03-03 (period of report 2026-02-28).
• Two award entries: 3,000 shares @ $0.00 (each), total 6,000 PSUs acquired (transaction code A = Award/Grant).
• Shares owned after the transaction: not specified in the filing.
• Footnote: F1 states the PSUs were originally awarded on February 22, 2024, and a portion vested upon achievement of individual performance objectives established June 24, 2024.
• No indication in the filing of tax withholding, a 10b5-1 plan, or late-filing penalties.

Context These entries reflect compensation in the form of performance share units that vested or were credited to the executive, rather than a cash purchase or sale of company stock. Awards like PSUs depend on pre-set performance criteria and do not by themselves indicate insider buying or selling intent in the open market; they are part of executive pay. Retail investors typically view outright purchases as stronger signals of insider conviction, while awards are routine compensation.